Vaccine dispute could cut Aspen’s earnings by R2bn
Africa’s biggest drug maker also warns the trade war could affect its business
22 April 2025 - 19:39
Aspen Pharmacare has called an abrupt investor call after it warned that its manufacturing business is facing a “material contractual dispute” that might lead to core earnings plunging by as much as R2bn.
The company, Africa’s biggest drug manufacturer, did not go into the details detail of the dispute. The group is expected to take investors into its confidence on Wednesday when it fields questions on the matter...
Would you like to comment on this article?
Sign up (it's quick and free) or sign in now.
Please read our Comment Policy before commenting.
Subscribe now to unlock this article.
Support BusinessLIVE’s award-winning journalism for R129 per month (digital access only).
There’s never been a more important time to support independent journalism in SA. Our subscription packages now offer an ad-free experience for readers.
Cancel anytime.
Questions? Email helpdesk@businesslive.co.za or call 0860 52 52 00. Got a subscription voucher? Redeem it now.